Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Author: Tamas Sohajda

Cyclolab R&D Director
December 9, 2021 Non-pharma applications / Pharma applications

Barentz Acquires Gangwal in India

Barentz International, a leading global life science ingredients distributor announced an agreement to acquire a majority stake in the distribution

Continue reading

December 8, 2021 CD derivatives / Pharma applications

Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant

Gilead has conducted an analysis of genetic information currently available for the Omicron variant and found no additional prevalent mutations

Continue reading

December 7, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through

Continue reading

November 18, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Submits IND Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

October 21, 2021 CD as API / Pharma applications

Parkinson’s Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-β-Cyclodextrin Treatment

OrganoTherapeutics in collaboration with University of Luxemburg has published interestingin vitro and in vivo results on the effects of HPBCD

Continue reading

October 14, 2021 CD as API / CD derivatives / Pharma applications

Alveron Pharma raises a further EUR 3.9 million to progress first in class cyclodextrin drug

Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111,

Continue reading

September 27, 2021 CD as API / CD derivatives / Pharma applications

Underdog Closes $10M Financing Round – the next cyclodextrin can be developed further as active

Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.

Continue reading

September 21, 2021 Drug delivery / Pharma applications

Marinus Announces FDA Acceptance for Filing and Priority Review of NDA for SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that

Continue reading

September 15, 2021 Drug delivery / Pharma applications

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced

Continue reading

September 9, 2021 CD as API / CD derivatives / Pharma applications

Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators

Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been

Continue reading

Posts navigation

1 2 3 … 14 Next Posts»

Recent Posts

  • Continuous flow synthesis of 6-monoamino-6-monodeoxy-β-cyclodextrin
  • Synergistic Antitumor Potency of a Self-Assembling Cyclodextrin Nanoplex for the Co-Delivery of 5-Fluorouracil and Interleukin-2 in the Treatment of Colorectal Cancer
  • Oculis goes public on the Nasdaq Stock Market
  • Special Issue “Drug Carriers Production Processes for Innovative Human Applications”
  • Anomalous Properties of Cyclodextrins and Their Complexes in Aqueous Solutions

Tags

alpha-CD antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (35)
  • CD as API (206)
  • CD derivatives (258)
  • Cosmetics and toilettry (21)
  • Drug delivery (440)
  • E-ducation (55)
  • Environmental (77)
  • Events (160)
  • Food (124)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (15)
  • Non-pharma applications (215)
  • Other industrial use (59)
  • Pharma applications (705)
  • Supramolecular systems (25)
  • Uncategorized (43)

Top Posts

  • Synergistic Antitumor Potency of a Self-Assembling Cyclodextrin Nanoplex for the Co-Delivery of 5-Fluorouracil and Interleukin-2 in the Treatment of Colorectal Cancer
  • Lanosterol eye drops for cataract treatment
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • Continuous flow synthesis of 6-monoamino-6-monodeoxy-β-cyclodextrin
  • How air fresheners work?
  • International Conference on Bioinspiration and Biobased​ Materials
  • Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)
  • Australian company pioneering Cavadextrin for regression of atherosclerosis
  • Midazolam/γ-cyclodextrin Premedication in Pediatric Anesthesia
  • Website of EuroCD Conference is open

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 523 other subscribers
 

Loading Comments...